Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PainReform ( (PRFX) ) has provided an update.
On January 7, 2026, PainReform Ltd. filed a Form 6-K in the United States providing updated financial disclosure related to its acquisition of LayerBio Inc., a transaction first announced in July 2025 and completed on August 13, 2025, in which PainReform acquired 7,331,378 preferred shares representing a 51% controlling stake. The filing supplies investors with unaudited pro forma condensed combined financial information as if the deal had occurred on January 1, 2024 and June 30, 2025, along with LayerBio’s audited financial statements for 2023 and 2024 and unaudited financials for the six months ended June 30, 2025, clarifying that the acquisition qualifies as a business combination but is less than 50% significant under SEC tests and that the pro forma figures are illustrative only, without assumed synergies or forward projections, to better inform stakeholders about the combined company’s historical financial profile.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is driven primarily by very weak financial performance (minimal revenue, widening losses, and worsening cash burn with a shrinking equity cushion). Technicals also weigh on the score due to a clear downtrend versus key moving averages, partially offset by oversold indicators. Valuation contributes little support given negative earnings and no dividend yield.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd., based in Tel Aviv, is a foreign private issuer in the pharmaceutical/biotech sector focused on developing pain-related therapeutics and technologies, and is listed in the United States where it files annual reports on Form 20-F and uses shelf registration statements on Form F-3 and equity plans on Form S-8 to support its capital-raising and compensation activities.
Average Trading Volume: 317,294
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.65M
For a thorough assessment of PRFX stock, go to TipRanks’ Stock Analysis page.